Stockscreener 앱 받기
12.72
2.50%
0.31
시간 외 거래:
12.72
전일 마감가:
$12.41
열려 있는:
$12.8
하루 거래량:
820.27K
Relative Volume:
6.24
시가총액:
$3.83B
수익:
$391.87M
순이익/손실:
$-441.45M
주가수익비율:
-6.8757
EPS:
-1.85
순현금흐름:
$-301.21M
1주 성능:
-2.08%
1개월 성능:
-3.85%
6개월 성능:
+8.72%
1년 성능:
-19.24%
1일 변동 폭
$12.70
$12.96
1주일 범위
$12.36
$13.08
52주 변동 폭
$9.15
$18.00
Alvotech Stock (ALVO) Company Profile
ALVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
12.72 | 3.83B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
170.90 | 77.10B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.47 | 42.82B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.39 | 42.45B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.73 | 20.09B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
151.82 | 15.37B | 2.24B | 385.90M | 440.10M | 3.73 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-09-21 | 개시 | Barclays | Equal Weight |
| 2022-09-07 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-06 | 다운그레이드 | Citigroup | Buy → Sell |
| 2022-07-26 | 개시 | Citigroup | Buy |
모두보기
Alvotech 주식(ALVO)의 최신 뉴스
Alvotech (NASDAQ:ALVO) Shares Gap UpHere's What Happened - MarketBeat
Short Interest in Alvotech (NASDAQ:ALVO) Rises By 244.2% - MarketBeat
Alvotech Breaks Below 200-Day Moving AverageNotable for ALVO - Nasdaq
FDA accepts Teva, Alvotech BLAs for Simponi biosimilars - MSN
Alvotech And Teva Claim First US Golimumab Filing - News & Insights
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket - Benzinga
Alvotech and Teva Announce Filing Acceptance of U.S. - GlobeNewswire
FDA accepts Teva, Alvotech BLAs for Simponi biosimilars (TEVA:NYSE) - Seeking Alpha
FDA Accepts Alvotech’s Biosimilar to Simponi (Golimumab) for Review - Contract Pharma
FDA Accepts Alvotech’s Biosimilar Applications for Review - TipRanks
Alvotech and Teva Pharmaceuticals Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, A Proposed Biosimilar to Simponi® and Simponi Aria® - Marketscreener.com
Alvotech og Teva tilkynna að FDA hefur tekið til umsagnar - GlobeNewswire
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) - GlobeNewswire Inc.
Alvotech's (NASDAQ:ALVO) largest shareholders are private equity firms with 34% ownership, private companies own 31% - Yahoo Finance
Private equity firms account for 34% of Alvotech's (NASDAQ:ALVO) ownership, while private companies account for 31% - Simply Wall St
J&J stands by sales growth ambitions—and points to potential Tremfya boon—as Stelara biosimilars take hold - FiercePharma
JB Hunt Transport Posts Weak Earnings, Joins JetBlue Airways And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket - Benzinga
Has Alvotech (ALVO) Outpaced Other Medical Stocks This Year? - MSN
Alvotech : Transactions of Managers and Closely Associated Persons - Marketscreener.com
Alvotech : Managers' transactionsALVOTECH -January 15, 2025 at 04:03 pm EST - Marketscreener.com
Alvotech (NASDAQ:ALVO) Sees Large Growth in Short Interest - MarketBeat
Alvotech birtir fjárhagsdagatal fyrir árið 2025 - GlobeNewswire
Alvotech Eyes Growth As Product Revenue Soars And New Launches ApproachWill The Stock Follow? - RTTNews
Are Medical Stocks Lagging Alvotech (ALVO) This Year? - Yahoo Finance
Alvotech (NASDAQ:ALVO) Short Interest Update - MarketBeat
Alvotech Joins Nasdaq Biotechnology Index, Boosting Industry Presence - TipRanks
Alvotech : Added to Nasdaq Biotech Index Effective Monday December 23, 2024 Form 6 K - Marketscreener.com
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 - The Manila Times
Alvotech Secures Coveted Spot in Nasdaq Biotechnology Index Following Strong Market Performance - StockTitan
ALVOAlvotech Ordinary Shares Latest Stock News & Market Updates - StockTitan
Wall Street Analysts Believe Alvotech (ALVO) Could Rally 39.83%: Here's is How to Trade - MSN
Alvotech's SWOT analysis: biosimilar powerhouse stock faces b2b model challenges - Investing.com
Is Alvotech (ALVO) Stock Outpacing Its Medical Peers This Year? - MSN
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration - The Center for Biosimilars
Alvotech (NASDAQ:ALVO) Is Expected To Breakeven In The Near Future - Simply Wall St
Short Interest in Alvotech (NASDAQ:ALVO) Rises By 47.8% - MarketBeat
Alvotech’s Eylea Biosimilar ‘Keeps In Mind’ US Patent Landscape - Citeline
Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth hurdles - Investing.com
Alvotech (ALVO) Shares Gap Down to $11.94 on Nov 22 - GuruFocus.com
Alvotech’s Position In The Coming Biosimilar Gold Rush (NASDAQ:ALVO) - Seeking Alpha
Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates - MSN
Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023) - Yahoo Finance
Earnings call: Alvotech reported revenues of $128 million - Investing.com India
Alvotech (ALVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.19%
0.06%
자본화:
|
볼륨(24시간):